![](/images/graphics-bg.png)
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
المؤلفون المشاركون
Busceti, Maria Teresa
Pelaia, Corrado
Calabrese, Cecilia
Garofalo, Eugenio
Vatrella, Alessandro
Pelaia, Girolamo
Terracciano, Rosa
Lombardo, N.
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-10
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns.
In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma.
The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2).
Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids.
Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma.
In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Pelaia, Corrado& Calabrese, Cecilia& Vatrella, Alessandro& Busceti, Maria Teresa& Garofalo, Eugenio& Lombardo, N.…[et al.]. 2018. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Pelaia, Corrado…[et al.]. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Pelaia, Corrado& Calabrese, Cecilia& Vatrella, Alessandro& Busceti, Maria Teresa& Garofalo, Eugenio& Lombardo, N.…[et al.]. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1126942
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)